Which postoperative combined therapy results in the best prognosis: radiochemocytokine therapy or aggressive chemotherapy?
The recurrence of esophageal cancer involving regional nodes, even in patients who have undergone curative surgery, often takes place within three years after surgery. Thus, a new multidisciplinary treatment including cytokines or aggressive chemotherapy with active nutritional support to improve the prognosis in cancer of the thoracic esophagus has been adopted.
Nishihira
T
T
Second Department of Surgery, Tohoku University School of Medicine, Sendai, Japan.
Hirayama
K
K
Akaishi
T
T
Shineha
R
R
Okayama
A
A
Mori
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000008:administration & dosage*; D011182:Postoperative Care; D011379:Prognosis; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
D016898:Interferon-alpha; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha